SLXP: Summary for Salix Pharmaceuticals, Ltd. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 8:10am EST - Canadian Markets open in 1 hour and 20 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Salix Pharmaceuticals Ltd. (SLXP)

On Feb 9: 26.97 USD 0.00 (0.00%)

MORE ON SLXP

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Salix Pharmaceuticals, Ltd. (NasdaqNM:SLXP) Delayed quote data

Last Trade:	26.97 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	26.97
Open:	N/A
Bid:	0.01 x 200
Ask:	27.64 x 200
1y Target Est:	36.89

Day's Range:	N/A - N/A
52wk Range:	6.14 - 29.91
Volume:	0
Avg Vol (3m):	838,210
Market Cap:	1.33B
P/E (ttm):	N/A
EPS (ttm):	-0.98
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add SLXP to Portfolio

Download Data

HEADLINES

•	The Biggest Growth Stocks in Health Care
	at Minyanville.com (Thu, Jan 28)

•	Bulls On Board For A Big Run From Salix
	at Forbes.com (Tue, Jan 26)

•	Salix upgraded ahead of FDA's Xifaxan decision
	AP (Tue, Jan 26)

•	Salix Pharm upgraded by Oppenheimer
	Briefing.com (Tue, Jan 26)

•	Lightning Round: Boeing, Cadbury, Fifth Third Bancorp and More
	at CNBC (Fri, Jan 8)

•	Salix slapped with lawsuit over OsmoPrep
	at bizjournals.com (Wed, Dec 23)

•	Suits Commenced Against Maker of Prescription Cleansing Drug
	PRNewswire (Wed, Dec 23)

•	Salix to File for IBS Indication
	Zacks.com (Wed, Dec 16)

•	Salix, FDA discuss new drug application
	at bizjournals.com (Fri, Dec 11)

•	SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Thu, Dec 10)

•	Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable B
	Business Wire (Thu, Dec 10)

•	SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Tue, Nov 24)

More Headlines for SLXP...

ANALYST

EPS Est (next year) (Dec-09) :	-0.89
EPS Est (in 2 years) (Dec-10) :	0.17
Avg Rec (current)*:	1.7
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•